Most analyses of intravenous tissue plasminogen activator (IV tPA) use for acute stroke in routine practice have been limited by sample size and generally restricted to patients treated in large academic medical facilities. In the present study, we sought to estimate among community hospitals the use of IV tPA and to identify factors associated with the use of IV tPA and inpatient mortality.
Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, Department of Neurology, School of Medicine, University of Washington, Seattle, Washington, USA.
